Stem cells give heart patients hope

By the Editorial Team · Thursday, October 1, 2026

A hospital in Japan completed the world’s first transplant of commercially produced heart muscle sheets derived from induced pluripotent stem cells into a patient with ischemic heart disease. This pioneering procedure, conditionally approved by the government, could improve heart function for patients with limited treatment options and will be studied further in up to 75 patients over the next decade.

A hospital in Japan has performed the world’s first surgery using commercially available sheets of heart muscle cells derived from induced pluripotent stem cells (iPS cells), marking a significant milestone in regenerative medicine. The procedure took place on Tuesday and involved transplanting lab-grown muscle tissue into the heart of a woman in her 50s.

This innovative therapy received conditional government approval in March and is aimed at patients with ischemic heart disease, a condition caused by narrowed arteries that restrict blood flow to the heart. The treatment is designed for individuals who have exhausted conventional options, with the goal of improving heart muscle function, reducing symptoms of heart failure, and enhancing cardiac performance and exercise capacity.

Yoshiki Sawa, the surgeon leading the operation and head of Osaka Keisatsu Hospital, expressed hope that the procedure would improve the patient’s quality of life. Sawa developed the technique in collaboration with Shinya Yamanaka, a Japanese scientist awarded the Nobel Prize in 2012 for his groundbreaking work on iPS cells, which have the ability to develop into any cell type in the body.

Prior clinical trials of the therapy were conducted on eight patients with ischemic heart disease. Reports indicate that all participants experienced relief from symptoms, with half showing measurable improvement in heart function. Following this initial success, Sawa and his team plan to perform similar surgeries on 75 patients by 2033 to gather further data on the treatment’s effectiveness and safety.

According to Japanese media, full authorization of the therapy is expected after a seven-year evaluation period that will assess its long-term benefits and risks. In addition to this heart treatment, Japan also granted conditional approval this year for an iPS cell-based therapy targeting Parkinson’s disease, involving the transplantation of these cells into the brain following encouraging trial results.

iPS cells are generated by reprogramming mature, specialized cells back into a more primitive state, offering the ability to grow various tissue types without the ethical concerns associated with embryonic stem cells. This advancement in biotechnology represents a promising frontier for treating conditions that currently have limited therapeutic options.

This article was reported by synthesizing coverage from multiple independent news outlets to present a balanced, unbiased account. Read about our editorial standards. Spotted an error? Let us know.